KR920700667A - Application of Intercellular Adhesion Molecules and Their Binding Ligands to Asthma Treatment - Google Patents

Application of Intercellular Adhesion Molecules and Their Binding Ligands to Asthma Treatment

Info

Publication number
KR920700667A
KR920700667A KR1019910701072A KR910701072A KR920700667A KR 920700667 A KR920700667 A KR 920700667A KR 1019910701072 A KR1019910701072 A KR 1019910701072A KR 910701072 A KR910701072 A KR 910701072A KR 920700667 A KR920700667 A KR 920700667A
Authority
KR
South Korea
Prior art keywords
group
glycoproteins
antibody
icam
binding
Prior art date
Application number
KR1019910701072A
Other languages
Korean (ko)
Other versions
KR0177519B1 (en
Inventor
디. 웨그너 크레이그
군델 로버트 에이취
로스레인 로버트
Original Assignee
원본미기재
베링거 인겔하임 파머수티칼 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 베링거 인겔하임 파머수티칼 인코포레이티드 filed Critical 원본미기재
Publication of KR920700667A publication Critical patent/KR920700667A/en
Application granted granted Critical
Publication of KR0177519B1 publication Critical patent/KR0177519B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of intercellular adhesion molecules (ICAM-1), their functional derivatives, and molecules which bind to them, in the treatment of asthma.

Description

세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용Application of Intercellular Adhesion Molecules and Their Binding Ligands to Asthma Treatment

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 ICAM-1 cDNA의 뉴클레오티드 및 아미노산 서열을 나타낸다. 제2도는 ICMA-1의 도메인 구조를 나타낸다. 제3도는 자극없이 단백질 피복된 편평한 바닥조직 배양판 웰 PAF(10-7M)자극과 함께 단백질 피복된 편형한 바닥조직 배양판웰, 면역착제(IC)피복되고 자극된 편평한 바닥조직배양판웰, 그리고 피복되지 않고 자극도 없는 편평한 바닥조직 배양판웰에의 호산성(eosinophil)점착을 나타낸다.1 shows the nucleotide and amino acid sequences of ICAM-1 cDNA. 2 shows the domain structure of ICMA-1. Figure 3 shows protein coated flat bottom tissue culture wells without stimulation, protein coated flat bottom tissue culture wells with PAF (10 -7 M) stimulation, immunocomposited (IC) coated and stimulated flat bottom tissue culture wells, and Eosinophil adhesion to uncoated, non-irritating flat bottom culture plate wells is shown.

Claims (19)

다음으로 구성되는 군으로부터 선택된 치료학적 유효량의 약제를 환자에게 제공하는 것으로 이루어지는 환자에게 천식을 치료하는 방법. (a) ICAM-1에 결합 할수 있는 항체, (b)ICAM-1에 결합할 수 있는 항체(a)의 단편, (c)천연오염물질이 실질적으로 없는 ICAM-1,(d)ICAM-1의 기능성유도체, (e)당단백질의 CD18족의 멤버에 결합할 수 있는 항체, (f)당단백질의 CD18족의 멤버에 결합할 수 있는 상기 항체(e)의 단편, (g) 천연오염물질이 실질적으로 없는 당단백질의 CD18족의 멤버, 그리고(h)당단백질의 CD18족의 멤버의 기능성 유도체.A method of treating asthma in a patient, comprising: providing the patient with a therapeutically effective amount of a medicament selected from the group consisting of: (a) an antibody capable of binding to ICAM-1, (b) a fragment of an antibody capable of binding to ICAM-1, (c) ICAM-1 substantially free of natural contaminants, (d) IICA-1 A functional derivative of (e) an antibody capable of binding to a member of the CD18 group of glycoproteins, (f) a fragment of the antibody (e) capable of binding to a member of the CD18 group of glycoproteins, (g) a natural contaminant A functional derivative of a member of the CD18 group of this substantially free glycoprotein and (h) a member of the CD18 group of glycoproteins. 제1항에 있어서, 상기 약제는 ICAM-1에 결합할수 있는 상기 항체(a), 또는 ICAM-1에 결합할 수 있는 상기 항체(a)의 단편인 것을 특징으로 하는 방법.The method of claim 1, wherein the medicament is the antibody (a) capable of binding ICAM-1 or a fragment of the antibody (a) capable of binding ICAM-1. 제2항에 있어서, 상기 항체(a)는 모노클로날 항체인 것을 특징으로 하는 방법.The method of claim 2, wherein the antibody (a) is a monoclonal antibody. 제3항에 있어서, 상기 모노클로날 항체는 모노클로날 항체 R6.5인 것을 특징으로 하는 방법.The method of claim 3, wherein the monoclonal antibody is monoclonal antibody R6.5. 제1항에 있어서, 상기 약제는 천연오염물질이 실질적으로 없는 ICAM-1인 것을 특징으로 하는 방법.The method of claim 1 wherein the medicament is ICAM-1 substantially free of natural contaminants. 제1항에 있어서, 상기 약제는 ICAM-1의 기능성 유도체인 것을 특징으로 하는 방법.The method of claim 1, wherein the medicament is a functional derivative of ICAM-1. ICAM-1 도메인 1을 함유하는 제6항의 ICAM-1의 기능성 유도체.The functional derivative of ICAM-1 of claim 6 containing ICAM-1 domain 1. ICAM-1 도메인 2를 함유하는 제6항의 ICMA-1의 기능성 유도체.The functional derivative of ICMA-1 of claim 6 containing ICAM-1 domain 2. ICMA-1 용해성 유도체인 제6항의 ICAM-1의 기능성 유도체.The functional derivative of ICAM-1 of claim 6 which is an ICMA-1 soluble derivative. 제1항에 있어서, 상기 약제는 당단백질의 CD18족의 멤버에 결합할 수 있는 상기 항체(e), 또는 당단백질의 CD18족의 멤버에 결합할 수 있는 상기 항체(e)의 단편인 것을 특징으로 하는 방법.The method of claim 1, wherein the medicament is characterized in that the antibody (e) capable of binding to a member of the CD18 group of glycoproteins, or a fragment of the antibody (e) capable of binding to a member of the CD18 group of glycoproteins How to. 제10항에 있어서, 상기 항체(e)는 당단백질의 CD18족의 상기 멤버의 알파아단위 결합할 수 있는 것을 특징으로 하는 방법.The method of claim 10, wherein the antibody (e) is characterized in that the binding of the alpha subunit of the member of the CD18 group of glycoproteins. 제10항에 있어서, 상기 항체(e)는 당단백질의 CD18족의 상기 멤버의 베타아단위 결합할 수 있는 것을 특징으로 하는 방법.The method of claim 10, wherein the antibody (e) is capable of binding to beta subunits of the member of the CD18 group of glycoproteins. 제1항에 있어서, 상기 약제는 천연오염물질이 실질적으로 없는 당단백질의 CD18족의 멤버인 것을 특징으로 하는 방법.The method of claim 1, wherein the medicament is a member of the CD18 group of glycoproteins substantially free of natural contaminants. 제13항에 있어서, 당단백질의 CD18족의 상기 멤버는 당단백질의 CD18족이 멤버의 알파아단위를 함유하는 것을 특징으로 하는 방법.15. The method of claim 13, wherein said member of the CD18 group of glycoproteins comprises the alpha subunit of the member of the CD18 group of glycoproteins. 제13항에 있어서, 당단백질의 CD18W족의 상기 멤버는 당단백질의 CD18족의 멤버의 베타아단위를 함유하는 것을 특징으로 하는 방법.The method of claim 13, wherein said member of the CD18W group of glycoproteins contains a beta subunit of the member of the CD18 group of glycoproteins. 제13항에 있어서, 당단백질의 CD18족의 상기 멤버는 당단백질의 CD18족의 멤버의 알파아 베타아 단위를 둘다 함유하는 것을 특징으로 하는 방법.The method of claim 13, wherein said member of the CD18 group of glycoproteins contains both alpha-beta bea units of members of the CD18 group of glycoproteins. 제13항에 있어서, 상기 약제는 당단백질의 CD18족의 멤버의 기능성 유도체인 것을 특징으로 하는 방법.The method of claim 13, wherein the medicament is a functional derivative of a member of the CD18 family of glycoproteins. 황원의 수회 흡입을 받은 사람아닌 포유동물에 상기 상기 약제를 투여하는 것으로 이루어지는 천식의 치료에 치료학적 효능을 가질수 있는 약제를 확인하는 방법.A method of identifying an agent that may have therapeutic efficacy in the treatment of asthma, comprising administering said agent to a mammal that is not a human who has been given multiple inhalations of sulfur. 제18항에 있어서, 상기 포유동물에서 기도 감응성의 어떤 증가는 메타콜린 또는 히스타민으로 측정되는 것을 특징으로 하는 방법.19. The method of claim 18, wherein any increase in airway sensitivity in the mammal is measured by methacholine or histamine. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019910701072A 1989-03-09 1990-03-09 Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma KR0177519B1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US32123989A 1989-03-09 1989-03-09
US32123789A 1989-03-09 1989-03-09
US32101889A 1989-03-09 1989-03-09
US321,239 1989-03-09
US321,237. 1989-03-09
US321,237 1989-03-09
US321,018 1989-03-09
US321,239. 1989-03-09
US32448189A 1989-03-16 1989-03-16
US324,481 1989-03-16
US324,481. 1989-03-16
US40140989A 1989-09-01 1989-09-01
US401,409. 1989-09-01
US401,409 1989-09-01

Publications (2)

Publication Number Publication Date
KR920700667A true KR920700667A (en) 1992-08-10
KR0177519B1 KR0177519B1 (en) 1999-03-20

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701072A KR0177519B1 (en) 1989-03-09 1990-03-09 Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma

Country Status (13)

Country Link
EP (1) EP0387701B1 (en)
JP (1) JP3119483B2 (en)
KR (1) KR0177519B1 (en)
AT (1) ATE79270T1 (en)
AU (1) AU638450B2 (en)
CA (1) CA2047721C (en)
DE (1) DE69000248T2 (en)
DK (1) DK0387701T3 (en)
ES (1) ES2035668T3 (en)
GR (1) GR3006073T3 (en)
HU (1) HU216313B (en)
NZ (1) NZ232868A (en)
WO (1) WO1990010453A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ES2141076T3 (en) 1988-09-01 2000-03-16 Bayer Ag HUMAN RHINOVIRUS RECEPTOR PROTEIN INHIBITING VIRUS INFECTIVITY.
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
ES2134762T3 (en) * 1990-07-20 1999-10-16 Bayer Ag MULTIMERICAL FORMS OF HUMAN RHINOVIRUS RECEPTOR PROTEINS.
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
CA2092801A1 (en) * 1990-10-03 1992-04-04 Randall Barton Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
DK0507187T3 (en) * 1991-04-03 1997-04-07 Boehringer Ingelheim Pharma Method for inhibiting pulmonary oxygen toxicity
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2083273A1 (en) * 1991-07-31 1993-02-01 Robert H. Gundel Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
CA2116109A1 (en) * 1992-06-22 1994-01-06 Jeffrey M. Greve Multimeric forms of human rhinovirus receptor protein
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc Multimeric proteins and methods of making and using same
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (en) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc INTERCELLULAR ADHESION MOLECULES AND THEIR FIXATION LINKS.
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
HU902883D0 (en) 1991-12-30
ES2035668T3 (en) 1993-04-16
AU638450B2 (en) 1993-07-01
JP3119483B2 (en) 2000-12-18
KR0177519B1 (en) 1999-03-20
JPH04504127A (en) 1992-07-23
GR3006073T3 (en) 1993-06-21
CA2047721C (en) 2004-01-06
DE69000248D1 (en) 1992-09-17
EP0387701B1 (en) 1992-08-12
DE69000248T2 (en) 1993-01-07
DK0387701T3 (en) 1992-12-07
WO1990010453A1 (en) 1990-09-20
AU5349990A (en) 1990-10-09
HUT65843A (en) 1994-07-28
HU216313B (en) 1999-06-28
NZ232868A (en) 1995-05-26
CA2047721A1 (en) 1990-09-10
EP0387701A1 (en) 1990-09-19
ATE79270T1 (en) 1992-08-15

Similar Documents

Publication Publication Date Title
KR920700667A (en) Application of Intercellular Adhesion Molecules and Their Binding Ligands to Asthma Treatment
ATE322283T1 (en) TRANSDERMAL USE OF SECRETIN TO TREAT AUTISM
ATE295176T1 (en) METHOD TO SUPPORT DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISTIC SYNDROME
DE69328550D1 (en) USE OF FULLEREN DERIVATIVES IN DIAGNOSTIC AND / OR THERAPEUTIC AGENTS
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
EA199800393A1 (en) COMPOSITIONS AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF DAMAGE OF BONES
ATE269978T1 (en) METHOD FOR DETERMINING THE PROGNOSIS OF A PATIENT WITH A NEUROLOGICAL DISEASE
BR0011000A (en) Methods to prevent or treat a disease associated with ab amyloid deposits in a patient's brain, to evaluate an antibody for the removal activity of a biological entity physically associated with an antigen and to detect an amyloid deposit in a patient, pharmaceutical composition, and, diagnostic set
DE69230112T2 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE
FI94028B (en) Device for the diagnosis and treatment of nasal diseases
BR0011103A (en) Pharmaceutical composition, and methods for the prevention or treatment of a disorder characterized by amyloid deposition in a mammalian subject, to determine the prognosis of a patient who is undergoing treatment for an amyloid disorder and for the prevention or treatment of a disease characterized by a amyloid deposit in a patient
DE69333321D1 (en) Use of a consensus interferon to reduce the side effects in the interferon treatment of viral hepatites.
DE69320646D1 (en) METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDEN DERIVATIVES AND AN S- OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE SUBSTANCE
ATE93138T1 (en) USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION.
Rao et al. The cholinergic neuronal differentiation factor from heart cell conditioned medium is different from the cholinergic factors in sciatic nerve and spinal cord
SE9201573D0 (en) USE OF IGF-1
ATE198278T1 (en) USE OF SULODEXIDE AND DRUGS CONTAINING IT FOR THE TREATMENT OF DIABETIC NEPHROPATHY
ATE220923T1 (en) RECOMBINANT ADENOVIRUSES AND THEIR USE IN GENE THERAPY FOR THE TREATMENT OF EYE DISEASES
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
ATE157010T1 (en) A COMPOSITION CONTAINING AMYLIN OR AMYLIN ANALOGUE, WHICH ALSO OPTIONALLY CONTAINS INSULIN, FOR THE TREATMENT OF ANOREXIA AND RELATED CONDITIONS
DE69428272T2 (en) LO-CD2A ANTIBODIES AND THEIR USE FOR INHIBITING T-CELL ACTIVATION AND GROWTH
Wu et al. Odontogenic Differentiation Induced by TGF-Β1 Binding Peptide–Modified Bioglass
ATE249832T1 (en) USE OF OLANZAPINE OR A SALT IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF AUTISM AND MENTAL RETARDATION
DE69829995D1 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HRV INFECTIONS
FI894592A (en) DIAGNOSTISERING AV OEVERFLOEDIG FETMA FOERORSAKAD AV GENETISK FOERORSAKAD OEFERFLOEDIG FETMA.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121109

Year of fee payment: 15

EXPY Expiration of term